Skip To Content

Living with
 myelofibrosis (MF) and anemia can be exhausting

If MF and anemia are affecting how you feel day to day and you rely on blood transfusions, you may be looking for another option. The ELRiSE MF Study is now enrolling adults with MF and anemia who are taking ruxolitinib. See if it’s right for you.
See If You May Qualify

You may be able to participate in the ELRiSE MF Study if you:

  • Are at least 18 years old
  • Have been diagnosed with myelofibrosis (MF)
  • Have anemia and require regular blood transfusions
  • Are currently taking ruxolitinib

If you are interested in participating, ask your doctor if this study may be right for you. The study doctor or staff will review additional study criteria with you.

Participants will receive all study-related care at no cost, and they may be reimbursed for travel and study-related expenses, where permitted by local laws and regulations.
See If You May Qualify

About the ELRiSE MF Study

The ELRiSE MF Study is evaluating an investigational study drug to learn if it can safely and effectively improve anemia and reduce the need for blood transfusions in people with MF and anemia who are taking ruxolitinib.

What to expect:

  • A screening period to determine eligibility
  • Regular study visits with a dedicated study team
  • An injection under the skin every 4 weeks
  • Ongoing monitoring throughout the study

During the initial treatment period, participants will receive either the investigational study drug or a placebo. A placebo is a substance that looks like the investigational study drug, but does not contain any active ingredients. Neither participants nor researchers will know which treatment is being given.

After this period, some participants may be eligible to continue into an open-label extension period where all participants receive the investigational study drug. Open-label means that both researchers and participants know which treatment is being given.

Total participation time varies but may last up to approximately 5 years.

For Healthcare Professionals

  • Phase 3, randomized, double-blind, placebo-controlled
  • Evaluating an investigational study drug for MF-related anemia in participants receiving concurrent ruxolitinib
  • Target enrollment: ~232–324 participants

Please consider patients with:

  • Myelofibrosis (primary, post-ET, or post-PV)
  • Ongoing transfusion requirements
  • Limited available treatment options

  • To evaluate whether the investigational study drug can improve anemia and reduce transfusion burden in participants with MF.

When discussing this clinical research study with your patients, here are some key points to mention: 

  • Participants will receive their assigned study drug administered as a subcutaneous injection approximately every 4 weeks
  • There will be an initial 36-week treatment period during which participants will receive either the investigational study drug or placebo
  • Some participants may be eligible for an open-label extension period during which all participants will receive the investigational study drug
  • Study-related care will be provided at no cost
  • Travel support may be available, where permitted by local laws and regulations
This clinical research study has the potential to offer a step forward in providing much-needed relief for people with MF and anemia. We are looking for physicians to review their patients’ charts to see if any of them may be eligible for participation.
See If You May Qualify